Pallidal origin of GABA release within the substantia nigra pars reticulata during high-frequency stimulation of the subthalamic nucleus by Windels, François et al.
Neurobiology of Disease
Pallidal Origin of GABA Release within the Substantia Nigra
Pars Reticulata during High-Frequency Stimulation of the
Subthalamic Nucleus
Franc¸ois Windels, Carole Carcenac, Annie Poupard, andMarc Savasta
Dynamique des Re´seaux Neuronaux, Unite´ Mixte de Recherche, Institut National de la Sante´ et de la Recherche Me´dicale, Unite´ 704, Universite´ Joseph
Fourier, Unite´ de Formation par la Recherche en Biologie, 38041 Grenoble Cedex 09, France
High-frequency stimulation of the subthalamic nucleus (HFS-STN) is an effective treatment for alleviating the motor symptoms of
parkinsonian patients. However, the neurochemical basis of its effects remains unknown.We showed previously that 1 h of HFS-STN in
normal rats increases extracellular glutamate (Glu) level in theoutputnuclei of the STN, the globuspallidus (GP), and the substantianigra
pars reticulata (SNr), consistent with an increase in the activity of STN neurons. HFS-STN also increases GABA levels in the SNr, but the
origin of this increase is unclear. We investigated the effectiveness of HFS-STN for improving Parkinson’s disease symptoms, using
intracerebralmicrodialysis to determine the extracellular Glu andGABA levels of theGP and SNr in response toHFS-STN in anesthetized
hemiparkinsonian rats [6-hydroxydopamine lesion of the substantia nigra pars compacta (SNc)]. Basal levels of Glu andGABA in the GP
and SNr were significantly higher in hemiparkinsonian than in intact rats. HFS-STN did not affect extracellular Glu level in the SNr of
hemiparkinsonian rats but doubled the level of GABA. Ibotenic acid lesion of the GP abolished the increase in GABA levels in the SNr
induced by HFS-STN in SNc-lesioned rats. These results provide neurochemical confirmation of the hyperactivity of the STN after
dopaminergic denervation and suggest that the therapeutic effects of HFS-STN may result partly from the stimulation of pallidonigral
fibers, thereby revealing a potential role for pallidal GABA in the inhibition of basal ganglial output structures during HFS-STN.
Key words: subthalamic nucleus; substantia nigra pars reticulata; glutamate; GABA; basal ganglia; high-frequency deep brain stimula-
tion; Parkinson’s disease; microdialysis
Introduction
The subthalamic nucleus (STN) is a major component of the
basal ganglia. It is involved in the transmission of cortical signals
to the output nuclei of the basal ganglia, the substantia nigra pars
reticulata (SNr), and the internal segment of the globus pallidum
(Kitai and Deniau, 1981; Joel and Weiner, 1997; Smith et al.,
1998). The STN plays a key role in the control of movement, and
abnormal hyperactivity of the STN consecutive to the loss of
dopaminergic (DA) cells in the substantia nigra pars compacta
(SNc) is thought to play a critical role in the expression of Par-
kinson’s disease (PD) symptoms (Miller and DeLong, 1987;
Hollerman and Grace, 1992; Bergman et al., 1994; Hassani et al.,
1996; Bevan et al., 2002). Thus, the STN constitutes a strategic
target for the neurosurgical treatment of advanced PD.
In the last decade, high-frequency stimulation of the STN
(HFS-STN) has become an increasingly used method to treat the
parkinsonian motor syndrome and has been reported to induce
clinical improvement in PD in both experimental animals and
humans and drastically reduce daily levodopa requirements and
dyskinesia (Benazzouz et al., 1993; Pollak et al., 1993; Limousin et
al., 1995; Krack et al., 1998, 2003; Krause et al., 2001). The effects
of HFS-STN look equivalent to those of an STN lesion (Benaz-
zouz et al., 1995), suggesting that it may act by silencing STN
neurons (Benabid et al., 2002; Dostrovsky and Lozano, 2002).
Indeed, in vitro electrophysiological recordings have shown that
HFS-STN may silence STN neurons via the depolarization-
induced blockade of their activity (Beurrier et al., 2001;
Magarinos-Ascone et al., 2002; Garcia et al., 2003). However, in
vivo studies have suggested that this type of stimulation may also
produce its beneficial effects by activating the axons of STN cells,
STNafferents, or fibers passing close to the stimulation site (Win-
dels et al., 2000, 2003; Dostrovsky and Lozano, 2002; Salin et al.,
2002; Vitek, 2002; McIntyre et al., 2004a,b)
We further investigated the mechanisms underlying the ef-
fects of STN stimulation by in vivo intracerebral microdialysis
analysis of the effects of HFS-STN on the extracellular glutamate
(Glu) and GABA levels of the globus pallidus (GP) and SNr in
normal and hemiparkinsonian rats.We also tested the hypothesis
that passing fibers are stimulated frompallidal neurons by assess-
Received Sept. 29, 2004; revised April 13, 2005; accepted April 13, 2005.
This work was supported by the Institut National de la Sante´ et de la Recherche Me´dicale, by European Commu-
nity Grant QLK6-1999-02173 (Fifth Framework Programme for Research and Development), and by Action Con-
certe´e Incitative Grant 02 2 0409 from the Ministe`re de la Recherche et des Nouvelles Technologies. We thank Drs.
Nicolas Hussy, Guy Chouvet, and Paul Krack for critical reading of this manuscript.
Correspondence should be addressed to Dr. Marc Savasta, Dynamique des Re´seaux Neuronaux, Unite´ Mixte de
Recherche, Institut National de la Sante´ et de la Recherche Me´dicale, Unite´ 704, Universite´ Joseph Fourier, Unite´ de
Formation par la Recherche en Biologie Batiment B, Domaine Universitaire, 2280 rue de la Piscine, BP 53, 38041
Grenoble Cedex 09, France. E-mail: msavasta@ujf-grenoble.fr.
F.Windels’ present address: National Institute onDrug Abuse/Intramural Research Program, 5500Nathan Shock
Drive, Baltimore, MD 21224.
DOI:10.1523/JNEUROSCI.0360-05.2005
Copyright © 2005 Society for Neuroscience 0270-6474/05/255079-08$15.00/0
The Journal of Neuroscience, May 18, 2005 • 25(20):5079–5086 • 5079
ing the effects of HFS-STN on Glu and GABA levels in the SNr in
normal and hemiparkinsonian rats with a unilateral GP lesion.
Materials andMethods
Animals. Studies were performed on male Sprague Dawley rats (Iffa
Credo, Les Oncins, France) weighing between 280 and 350 g and housed
under standard laboratory conditions (12 h light/dark cycle) with food
and water provided ad libitum. Protocols conformed to the National
Institutes of Health Guide for the Care and Use of Laboratory Animals
(publication 865-23) and French Ministry of Agriculture regulations
(authorization number 03-441).
Lesion procedures. All animals were anesthetized with chloral hydrate
(400 mg/kg, i.p.) and secured in a Kopf stereotaxic apparatus (Phymep,
Paris, France). For SNc lesioning, 15 animals, treated previously with
desipramine (25 mg/kg, s.c.) to protect noradrenergic neurons, received
an injection into the left SNc of 12g of 6-hydroxydopamine (6-OHDA)
(Sigma, St. Quentin-Fallavier, France), dissolved in 4 l of sterile 0.9%
NaCl and 0.2% ascorbic acid, at a flow rate of 0.5l/min. The stereotaxic
coordinates of the injection site relative to the bregma were anteropos-
terior (AP),5.3mm, lateral (L),2.35mm, anddorsoventral (DV), 7.5
mm,with the incisor bar at 3.3mmbelow the interaural plane, according
to the stereotaxic atlas of Paxinos and Watson (1982). After injections,
animals were kept warm and allowed to recover from anesthesia. They
were returned to the animal facility for 3 weeks, by which time the de-
generation of DA neurons induced by the neurotoxin had stabilized, and
were processed for microdialysis experiments. For unilateral GP lesions,
15 rats received local injections of 0.5 g of ibotenic acid (Research
Biochemicals, Illkirch, France). Ibotenic acid was dissolved in sterile
NaCl (1 mg/ml) and infused at a flow rate of 0.2 l/min into the left GP.
Injections were performed at two sites per GP (0.5 l each) to achieve
homogeneous lesions (Konitsiotis et al., 1998; Miwa et al., 1998). Injec-
tion coordinates relative to the bregma were as follows: (1) anterior site:
AP,1.9 mm; L, 2.5 mm; DV, 6.5 mm; and (2) posterior site: AP,1.2
mm; L, 3 mm; DV, 6.8 mm. For unilateral combined lesions (SNc plus
GP), 15 rats were used, and there was a 5 d interval between the nigral
6-OHDA and injections of pallidal ibotenic acid.
Implantation of microdialysis probes and stimulation electrode. Rats
were anesthetized by inhalation (1 L/min) of a 3% halothane/air mixture
(22% O2, 78% N2) and mounted in a stereotaxic frame (David Kopf
Instruments, Tujunga, CA). The dorsal skull was exposed, and holes were
drilled to facilitate the lowering of the dialysis probes bilaterally into the
GP or the SNr and implantation of the stimulation electrode (left side,
i.e., the same side as the 6-OHDA injection) in the STN. Stereotaxic
coordinates were chosen according to the atlas of Paxinos and Watson
(1982) andwere as follows, relative to the bregma: (1)GP: AP,1mm; L,
3mm; DV, 7.2 mm; (2) SNr: AP,5.5 mm; L, 2.5 mm; DV, 8.4 mm; and
(3) STN: AP, 3.7 mm; L, 2.5 mm; and DV, 8.4 mm. During microdi-
alysis experiments, body temperature was maintained at 37°C with a
feedback-controlled heating pad (Harvard Apparatus, Edenbridge, UK),
and anesthesia was maintained by allowing the animal to inhale a 1%
halothane/air mixture (1 L/min).
Electrical stimulation.Concentric stimulating bipolar electrodes (outer
diameter, 200 m; model NEX-100; Rhodes Medical Instruments,
Woodland Hills, CA) were used. Stimuli were delivered with a World
Precision Instruments (Stevenage, UK) acupulser and a stimulus isola-
tion unit. Stimulation parameters corresponded to those used in clinical
practice [frequency, 130 Hz, 60 s rectangular pulse width, and 500 A
(3 V) intensity]. At the end of each experiment, an electrical lesion of the
STN was made to check the electrode localization postmortem.
Microdialysis. Homemade microdialysis probes were prepared and
used as described previously (Windels et al., 2000, 2003; Bruet et al.,
2003). These consisted of a concentric arrangement of a stainless-steel
tube (outer diameter, 0.4 mm) (Hamilton, Bonaduz, Switzerland) and a
piece of polyethylene tubing (outer diameter, 1.09 mm) (Merck, Darm-
stadt, Germany) into which we placed a piece of silica tubing (outer
diameter, 150m) (Merck). The silica tubing extended beyond the distal
end of the steel tube and was covered by a cuprophan tubular dialysis
membrane (Hospal, Lyon, France) sealed at the bottom. The length of
the dialysis membrane was adapted according to the size of the brain
nuclei studied: 2 mm for the GP and 1 mm for the SNr. The perfusion
liquid flowed out of the distal end of the steel tube, passing proximally
between the tube and the membrane (Tossman and Ungerstedt, 1986).
The probes were perfused with artificial CSF (in mM: 149 NaCl, 2.8 KCl,
1.2 MgCl2, 1.2 CaCl2, and 5.4 glucose, pH 7.3) at a flow rate of 1 l/min.
Before implantation, each probe was tested in vitro in a standard amino
acid solution to determine the recovery of amino acids (Tossman and
Ungerstedt, 1986). After implantation, dialysate fractions were collected
at 8 min intervals. The first 16 fractions were discarded to avoid the
effects of parenchymal disturbance so that an approximate steady-state
level was reached. The following eight fractions (64 min) were then col-
lected to determine basal values, and the next eight dialysate fractions
were collected during HFS-STN. Poststimulation effects were evaluated
for2 h by collecting the next 16 fractions.Dialysateswere automatically
collectedwith a refrigerated autosampler (Univentor, Zejton,Malta) and
stored at80°C until analysis.
Glutamate and GABA assay. The levels of Glu and GABA in the dialy-
sate fractions were determined by using HPLC with fluorimetric detec-
tion, as described previously (Donzanti andYamamoto, 1998;Windels et
al., 2000). Briefly, samples and standards were derivatized with
o-phthaldialdehyde. The injection was automatically processed by a re-
frigerated autoinjector (SIL 10 AXL; Shimadzu, Tokyo, Japan) into a 3
m C18 reversed-phase column (100  4.6 mm). The mobile phase
consisted of 0.05 M NaH2PO4, pH 5.8, with 12% acetonitrile, flowing at 1.2
ml/min and delivered by a Shimadzu LC-10AT pump. Extracellular lev-
els of amino acids were estimated by rationing peak areas of each amino
acid and their respective external standard (analytical software class
LC10; Shimadzu). The running time for each determination was 30min.
Histology. At the end of microdialysis experiments, animals without
6-OHDA-induced lesions (n 8)were killed by decapitation under deep
anesthesia; their brains were quickly removed from the skull and frozen
in isopentane at 30°C. All animals bearing 6-OHDA lesions (n  30)
were perfused transcardially under chloral hydrate anesthesia with 100
ml of 0.9% NaCl, pH 7.2, supplemented with heparin (5 104 IU/ml),
followed by 350ml of cold fixative consisting of 4%paraformaldehyde in
0.1 M PBS, pH 7.3 (in mM: 2.6 KCl, 1.4 KH2PO4, 136 NaCl, and 8
NaH2PO4). Brains were quickly removed and immersed overnight at 4°C
in 25% sucrose in 0.1 M phosphate buffer, pH 7.5, frozen in cooled
(40°C) isopentane, and then stored at 30°C. Serial frontal sections
(30 m thick) were cut with a cryostat microtome (Microm HM 500;
Microm, Francheville, France). The correct location of the microdialysis
probes and stimulation electrode was checked by collecting several tissue
sections at the pallidal, nigral, and STN levels, according to the atlas of
Paxinos andWatson (1982). The tissue sections were processed for clas-
sical cresyl violet staining. These histological controls were systematically
performed for all of the animals of each experimental group. All animals
presenting internal bleeding around the dialysis probes or electrodes
were excluded (to prevent contamination of the microdialysates) (n 
2), as were animals with misplaced microdialysis probes or stimulation
electrodes (n  3). To assess the dopaminergic denervation induced by
the nigral 6-OHDA injection, several tissue sections at the striatal and
nigral levels from fixed brains of lesioned animals were processed by
tyrosine hydroxylase (TH) immunohistochemistry. In this case, free-
floating sections were thoroughly washedwith TBS and incubated for 1 h
in 0.3% Triton X-100 in TBS (TBST) and 3% normal rabbit serum
(Miles, Elkhart, IN). Sections were then incubated with primary antisera
diluted in TBST containing 1% normal rabbit serum and 1% sodium
azide for 48 h, with shaking, at 4°C. The antiserum was diluted 1:100 for
TH (mouse monoclonal; Roche Diagnostics, Meylan, France). Antibody
binding was detected using the avidin–biotin–peroxidase complex. Dia-
minobenzidine (0.05%; Sigma)was used as chromagen, and 0.01%H2O2
(Merck, Rahway, NJ) was applied for 2–5 min, as described previously
(Gesdon et al., 1979). Sections were then dehydrated, mounted in Eukitt,
and covered with a coverslip before microscopy. GP lesions were evaluated
by lightmicroscopy to assess the loss of cell bodies and toobserve the intense
gliosis reaction leading to a shrinkage of this structure (see Fig. 2D).
Statistical analysis. The basal levels of the assayed substances were ex-
pressed as the concentrations found in the dialysates. Basal levels of the
amino acids in the SNr and GP between the different experimental
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groups were analyzed with a Mann–Whitney U test. When data were
expressed as percentages of controls, the average concentration of the
eight samples preceding the HFS-STN was defined as 100%. The HFS-
STN effects on extracellular Glu and GABA levels were analyzed with
one-way ANOVA with repeated measures over time. Comparisons with
prestimulation baseline were performed using a Dunnett’s or Games–
Howell test. A level of p  0.05 was considered critical for statistical
significance.
Results
Histological controls
Three weeks after injection, all animals receiving a unilateral in-
jection of 6-OHDA (n 30) showed amassive loss of TH immu-
nolabeling in the SNc (Fig. 1A) and in the striatum (caudate–
putamen nucleus) (Fig. 1B) on the lesioned side. Dense TH
immunolabeling was detected throughout the SNc, the ventral
tegmental area, the striatum, the nucleus accumbens, and the
olfactory tubercles on the intact side in 6-OHDA-injected rats
(Fig. 1A,B). Figure 2, B, F, and H, illustrates the correct implan-
tation of the microdialysis probe in the parenchyma of the GP
(Fig. 2B) and SNr (Fig. 2F) and of the stimulation electrode in the
STN (Fig. 2H). The symmetric location of microdialysis probes
made it possible to directly compare the bilateral data obtained
from homologous anatomical areas. Figure 2D shows the mas-
sive loss of neuronal cell bodies and gliosis within the lesioned
GP, with respect to the intact side (Fig. 2C).
Basal levels of extracellular Glu and GABA in the SNr and GP
are higher in hemiparkinsonian rats
Lesioning the SNcwith 6-OHDAdramatically increased the basal
level of Glu in output nuclei of the STN, the SNr, and theGP (Fig.
3A, Table 1), ipsilaterally to the lesion. In the SNr of SNc-lesioned
rats, the mean Glu level was 4.21  0.81 M (n  5), 9.5 times
( p 0.05) the basal levels reported previously for control intact
animals (0.44 0.06 M; n 7) (Windels et al., 2000). The Glu
level in the GP was 16 times higher ( p  0.05) in SNc-lesioned
animals (10.53 1.36 M; n 6) than in controls (0.65 0.04
M; n 6) (Windels et al., 2000). In contrast, lesioning of the GP
did not result in significant changes in basal Glu levels in the SNr
(0.27 0.13M; n 6, not significantly different from controls)
(Fig. 3A, Table 1), and did not prevent the increase in Glu level
induced by 6-OHDA treatment, with a level 2.6 and 3.4 times
higher (1.15 0.27M; n 6; p 0.05) inGP plus SNc-lesioned
rats than in control and GP-lesioned animals, respectively. Al-
though this increase in Glu levels remained detectable in GP plus
SNc-lesioned rats, it was significantly lower ( p 0.05) (Fig. 3A)
inGPplus SNc-lesioned rats than in SNc-lesioned animals. These
high Glu levels in basal conditions (i.e., before HFS-STN) in the
SNr andGP of hemiparkinsonian rats probably resulted from the
hyperactivity of STNneurons induced by the SNc lesion (Hassani
et al., 1996).
Interestingly, 6-OHDA treatment also doubled the mean
basal GABA level in both the SNr, from 0.028 0.09M in intact
animals (n 6) to 0.056 0.03 M in SNc-lesioned rats (n 5;
p 0.05), and the GP, from 0.048 0.002M in control animals
(n 6) to 0.094 0.02M in SNc-lesioned rats (n 6; p 0.05)
(Fig. 3B, Table 1). Basal GABA in the SNrmay be releasedmostly
by GABAergic fibers originating from theGP, because GABAwas
not detected in the SNr after lesioning of the GP. However, le-
sioning of the SNc with 6-OHDA increased the basal level of
GABA in the SNr, with a level of 0.02 0.01M (n 6) recorded
in GP plus SNc-lesioned rats (Fig. 3B, Table 1).
HFS-STN in hemiparkinsonian rats does not affect SNr
extracellular Glu levels but increases GABA levels
In SNc-lesioned rats, HFS-STN induced no change in the Glu
levels of both the SNr (n 5) and the GP (n 6) on the stimu-
lated (ipsilateral to the SNc lesion) or the unstimulated (con-
tralateral) side (Fig. 4, Table 1). Glu levels remained stable at
around baseline values throughout themicrodialysis experiment.
This effect is in contrast to that of HFS-STN in intact rats, which
strongly increases Glu levels in the SNr and GP (Table 1)
(Windels et al., 2000). Thus, STN stimulation in SNc-lesioned
rats fails to affect extracellular Glu levels in the output nuclei,
possibly because the basal Glu level was already increased consid-
erably by the dopaminergic lesion.
The picture regarding the effect of HFS-STN on GABA levels
was very different. In contrast towhatwas observed forGlu levels,
HFS-STN induced a gradual increase in the extracellular GABA
level in 6-OHDA-treated rats in the ipsilateral SNr during the 1 h
HFS period (fractions 8–16). This increase was maximal in the
last 16 min of the stimulation period (112 25%; n 5; p
0.05) (Fig. 5A). GABA level remained high during the poststimu-
lation period through fractions 17–24 and then gradually de-
creased. This effect was specific to the ispilateral side, because the
HFS-STNdid not affect extracellularGABA level in the contralat-
eral SNr (n 5) (Fig. 5A). This effect is similar to that reported
Figure1. Photographs of TH-immunostained coronal rat-brain sections at thenigral (A) and
striatal (B) levels in 6-OHDA-lesioned rats. Note the DA cell loss in the SNc (A) and the DA
terminal loss in the striatum (B) on the lesioned side. CPu, Caudate–putamen nucleus; VTA,
ventral tegmental area. Scale bar, 1 mm.
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previously in intact rats (Table 1) (Windels et al., 2000). In con-
trast, HFS-STN did not affect the GABA level in the GP in either
6-OHDA-treated rats (n  6) (Fig. 5B) or intact animals (Win-
dels et al., 2000).
The HFS-STN-induced increase in SNr GABA level requires
an intact GP
To check whether the source of GABA in the SNr could be the
pallidonigral GABAergic fibers stimulated byHFS-STN, wemea-
sured the variations in Glu and GABA levels in the ipsilateral SNr
of GP-lesioned andGP plus SNc-lesioned rats. GP lesions did not
prevent the increase in extracellular Glu level in the SNr elicited
by HFS-STN in nonhemiparkinsonian rats, with a significant
Figure 2. Photographs of cresyl violet-stained coronal rat-brain sections at pallidal (B–D),
nigral (F ), and subthalamic (H ) levels and schematic diagrams (A, E, and G) adapted from the
stereotaxic atlas of Paxinos andWatson (1982).B,F,H, Tissue sections at pallidal (B), nigral (F ),
Figure 3. Basal levels of extracellular nigral and pallidal glutamate (A) and GABA (B) in
controls and SNc-lesioned, GP-lesioned, and GP plus SNc-lesioned rats. *p 0.05 compared
with controls; #p 0.05, comparison between SNc-lesioned and GP plus SNc-lesioned rats;
ƒp 0.05, comparison between GP-lesioned and GP plus SNc-lesioned rats. Values presented
for the control group correspond to those obtained in a previous study (Windels et al., 2000).
Error bars represent SEM.
4
and subthalamic (H ) levels in hemiparkinsonian rats. Note the adequate implantation of mi-
crodialysis probes in the GP (B) and SNr (F ) and the adequate localization of the stimulation
electrode within the STN (H ). H, Asterisk indicates stimulation point. Scale bar, 1 mm. C, D,
Coronal sections at a higher magnification at the pallidal level (corresponding to the area de-
limited by a square in A) in GP-lesioned animals on the intact (C) or lesioned (D) side. Note the
loss of neuronal cell bodies and the gliosis in the lesionedGP (D) after the twomicroinjections of
0.5 ml of ibotenic acid solution (1 mg/ml). Scale bar, 40m. CPu, Caudate–putamen nucleus;
Hi, hippocampus; LV, lateral ventricle.
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70 10% maximum increase (n 6; p 0.05) obtained in the
fifth fraction after the beginning of stimulation (Fig. 6A, Table 1).
However, the increase in Glu level detected here, probably
through the excitation of intact subthalamonigral neurons, is of
lower amplitude in GP-lesioned animals than in controls. Extra-
cellular Glu level remained significantly high and stable through-
out the poststimulation period. In 6-OHDA-treated rats, lesion-
ing of the GP did not change the absence of effect of HFS-STN on
the SNr Glu level (n 6) (Fig. 6B, Table 1).
In contrast, the increase in the SNr GABA level induced by
HFS-STN in intact rats was not observed inGP-lesioned rats (n
6) (Fig. 6B, Table 1). GABAwas undetectable before, during, and
after HFS-STN. Similarly, the HFS-STN-induced increase in the
SNrGABA level seen in rats with SNc lesionswas abolished in rats
bearing GP plus SNc lesions (Fig. 6B). Therefore, the increase in
GABA level in the SNr induced by stimulation probably involved
stimulation of the GABAergic fibers originating from the GP.
Discussion
SNc lesions induced a dramatic increase in extracellular Glu level
in both the SNr and the GP. This extracellular Glu could come
from STN axon terminals, glial cells, or both (Danbolt, 2001;
Parpura et al., 2004). However, STN lesioning strongly decreases
Table 1. Extracellular concentrations of glutamate and GABA (expressed as amicromolar concentration) measured in the SNr (n 5–6) and GP (n 6–7) on the
stimulated side of intact, SNc-lesioned, GP-lesioned, and GP plus SNc-lesioned rats in basal conditions and under HFS-STN
Nuclei
Intacta SNc lesion GP lesion GP plus SNc lesions
Basal HFS-STN Basal HFS-STN Basal HFS-STN Basal HFS-STN
Glutamate (M) SNr 0.44 0.06 1.17 0.16 4.21 0.81 3.87  0.46 0.27  0.13 0.45  0.04 1.15  0.27 1.03  0.15
(166%; p 0.01) (no effect) (70%; p 0.05) (no effect)
GP 0.65 0.04 1.76 0.11 10.5 1.36 9.65  0.58
(172%; p 0.01) (no effect)
GABA (M) SNr 0.028 0.009 0.049 0.015 0.056 0.013 0.118  0.029 Not detectable Not detectable 0.02  0.01 0.022  0.01
(76%; p 0.05) (112%; p 0.05) (no effect)
GP 0.048 0.03 No effect 0.094 0.02 0.086  0.01
(no effect)
Values presented for the intact rats correspond to those obtained in our previous study (Windels et al., 2000).
Figure 4. Extracellular glutamate levels determined at 8min intervals in the SNr (A) and GP
(B) ipsilateral or contralateral to the stimulation in 6-0HDA SNc-lesioned rats. The prestimula-
tion period (PRE-STIM; fractions 1–8) gave eight dialysates, whereas the stimulation period
(STIM; fractions 9–16) and poststimulation period (POST-STIM; fractions 17–36) gave eight
and 20 dialysates, respectively. The mean SEM of the eight dialysates collected before HFS-STN
wasusedasthebaseline.Resultsareexpressedasapercentageofvariationofthisbaselinevalue.Each
percentage represents themean variations SEM calculated from six animals. Note that Glu levels
werenot affected significantly byHFS-STNoneither side in theGPandSNr. Error bars represent SEM.
Figure 5. Extracellular GABA levels determined at 8 min intervals in the SNr (A) and GP (B)
ipsilateral or contralateral to stimulation in 6-OHDA SNc-lesioned rats (B). The prestimulation
period (PRE-STIM; fractions 1–8) gave eight dialysates, whereas the stimulation period (STIM;
fractions 9–16) and poststimulation period (POST-STIM; fractions 17–36) gave eight and 20
dialysates, respectively. Themean SEM of the eight dialysates collected before HFS-STNwas
used as the baseline. Results are expressed as a percentage of variation of this baseline value.
Each percentage represents the mean variations SEM calculated from six animals. The data
were analyzed using a one-way ANOVA test with repeated measures over time followed by a
Dunnett’s or Games–Howell test (n 6 in each group). For SNr, F(2,24) 21.68 and p 0.05.
Note the increase in extracellular GABA level induced by HFS-STN in the SNr ipsilateral to the stim-
ulatedside,withnosignificantchangeinGPoneitherside.*p0.05comparedwithbaselinevalues.
Error bars represent SEM.
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(by 80%) the basal Glu level in the SNr
(Rosales et al., 1997) and its increase in
response to HFS-STN (our unpublished
observation). Therefore,most of the extra-
cellular Glu detected in the output nuclei
of the STN is probably linked to STN neu-
ron activity. Such observations thus provide
neurochemical confirmationof thehyperac-
tivity of subthalamopallidal and subthalam-
onigral pathways induced by dopaminergic
denervation. An increase in GABA level,
smaller than the Glu level, was also mea-
sured in both SNr and GP in hemiparkin-
sonian rats. HFS-STN in hemiparkinso-
nian rats did not increase the already high
level of Glu in the SNr but strongly in-
creased the level of GABA. A lesion of the
GP had little effect on the Glu level in the
SNr, indicating an absence of hyperactivity
of the STN not predicted by the “classic”
model of basal ganglia functioning (Albin
et al., 1989). Moreover, the GP lesion did
not prevent the increase in basal levels of
Glu in the SNr induced by the 6-OHDA
treatment, suggesting that STN hyperactivity is not simply a con-
sequence of the decrease in GP activity. Last, GP lesion com-
pletely abolished basal and stimulated GABA in the SNr. This
suggests thatGPGABAergic neurons constitute amajor source of
GABA in the SNr and that the stimulation of passing pallidoni-
gral GABAergic fibers by HFS-STN is involved in its effects on
basal ganglia output activity. These new data suggest that we
should reevaluate the true contribution of the STN andGP to the
effects of dopaminergic denervation and reconsider the mecha-
nisms involved in HFS-STN effects.
Changes in basal Glu and GABA level induced by
SNc lesioning
Many studies have shown that the loss of dopaminergic nigral
neurons in animals and PD patients leads to hyperactivity of the
subthalamopallidal, subthalamonigral, and corticostriatal path-
ways (Miller and DeLong, 1987; Bergman et al., 1990, 1994; De-
Long, 1990; Hollerman and Grace, 1992; Calabresi et al., 1993;
Bevan et al., 2002; Levy et al., 2002). Changes in STN firing prob-
ably lead to abnormal activity of basal ganglia output nuclei and
to motor disturbances attributable to imbalance between the di-
rect striatonigral and the trans-subthalamic pathways (Albin et
al., 1989; Lannes andMicheletti, 1994; Chesselet and Delfs, 1996;
Obeso et al., 1997). The large increase in Glu level in the SNr and
GP in hemiparkinsonian rats under anesthesia is consistent with
previous electrophysiological data showing that SNc lesion in-
creases the discharge rate of STN neurons; the discharge pattern
of these cells is alsomore “bursty” after SNc lesion (Hassani et al.,
1996). This increase in Glu level in the SNr, whichmay reflect the
hyperactivity of STNneurons, cannot solely be attributable to the
removal of pallidal inhibition, because it persists in rats with GP
plus SNc lesions. Similar conclusions were reached by Hassani et
al. (1996), who evaluated the effects of pallidal and SNc lesions on
electrophysiological activity in STN neurons. The change in SNr
Glu levels after dopaminergic denervation may be attributable to
an effect restricted to the STN or related structures. Many studies
have reported direct dopaminergic innervation of the STN
(Brown et al., 1979;Meibach andKatzman, 1979; Campbell et al.,
1985; Hassani et al., 1997; Smith et al., 1998), which may control
STN neuron activity directly or via presynaptic modulation of
neurotransmitter release (Kreiss et al., 1997; Ni et al., 2001; Shen
et al., 2003; Cragg et al., 2004).
The level of GABA in the SNr also increased in hemiparkin-
sonian rats. SNr neurons receive dense GABAergic inputs from
the striatum, GP, and SNr neurons themselves, via axon collater-
als playing a major role in the regulation of SNr neuron activity
(Albin et al., 1989; Alexander and Crutcher, 1990; Mink, 1996;
Celada et al., 1999). No basal GABA was detected in the SNr of
rats with GP lesions, indicating that most of this GABA comes
from the GP. This result is consistent with previous electrophys-
iological data suggesting that pallidonigral inputs predominate
(Celada et al., 1999). GP lesion did not prevent the increase in
basal GABA induced by dopaminergic denervation but may have
decreased it. Thus, although part of the increase in nigral GABA
may result from an increase in the activity of GP neurons
(through the increase in Glu release from STN neuron termi-
nals), other major sources of GABA, such as SNr neuron collat-
erals or other structures, appear to be involved.
Effects of HFS-STN
HFS-STN is an effective treatment for PD, but the mechanisms
involved are unclear (Benabid et al., 2002; Dostrovsky and
Lozano, 2002; Vitek, 2002; McIntyre et al., 2004a,b). In parkin-
sonian patients and animal models of PD, lesion (Bergman et al.,
1990; Aziz et al., 1991; Guridi andObeso, 2001) or pharmacolog-
ical inactivation of the STN and HFS-STN (Benazzouz et al.,
1993;Wichmann et al., 1994; Limousin et al., 1995, 1998; Krack et
al., 2003) have similar beneficial effects on PDmotor symptoms.
Consequently, it has been suggested that HFS-STN may inhibit
STN neuronal activity, reducing the excitatory drive of basal gan-
glia output nuclei. Such an effect has been observed in electro-
physiological studies in vivo (Burbaud et al., 1994; Benazzouz et
al., 1995, 2000; Tai et al., 2003) and in vitro (Beurrier et al., 2001;
Magarinos-Ascone et al., 2002). However, recent electrophysio-
logical data have shown that HFS-STN in monkeys increases the
activity of basal ganglia output nuclei (Hashimoto et al., 2002,
2003) and thatHFSmay drive the STN activity of rat slices in vitro
(Garcia et al., 2003). Consistent with these observations, we re-
ported previously that extracellularGlu andGABA levels increase
Figure 6. A, Extracellular Glu levels determined at 8 min intervals in the SNr ipsilateral to stimulation in ibotenic acid GP-
lesioned rats. The prestimulation period (PRE-STIM; fractions 1–8) gave eight dialysates, whereas the stimulation period (STIM;
fractions 9–16) and poststimulation period (POST-STIM; fractions 17–30) consisted of eight and 14 dialysates, respectively. The
mean SEM of the eight dialysates collected before HFS-STNwas used as the baseline. Results are expressed as a percentage of
variation of this baseline value. Each percentage represents the mean variations SEM calculated from five animals. The data
were analyzed using a one-way ANOVA test with repeated measures over time followed by a Dunnett’s or Games–Howell test
(n 5). For SNr, F(2,18) 23.456 and p 0.05. Note the increase in extracellular Glu level induced by HFS-STN on the ipsilateral,
stimulatedside.*p0.05comparedwithbaselinevalues.B,C, ExtracellularGlu (B)andGABA(C) levels,determinedat8min intervals in
theSNr ipsilateral tostimulationinGPplusSNc-lesionedrats.Theprestimulationperiod(fractions1–8)gaveeightdialysates,whereasthe
stimulation (fractions9–16) andpoststimulation (fractions17–36)periodsgaveeight and20dialysates, respectively. ThemeanSEM
oftheeightdialysatescollectedbeforeHFS-STNwasusedasthebaseline.Resultsareexpressedasapercentageofvariationofthisbaseline
value.Eachpercentagerepresents themeanvariationsSEMcalculatedfromfiveanimals.NotethatHFS-STNdidnotaffectextracellular
Glu andGABA levels on the ipsilateral, stimulated side. Error bars represent SEM.
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in the SNr during HFS-STN, suggesting the involvement of both
excitatory and inhibitory fibers in the action of HFS-STN
(Savasta et al., 2002).
We showed here that dopaminergic denervation prevented
the increase in Glu level in both the GP and SNr normally trig-
gered byHFS-STN in intact rats. This lack of effect onGlu level in
STN target nuclei may be attributable to the hyperactivity of STN
neurons in hemiparkisonian rats, with the level of Glu released
already being too high for additional increase under stimulation.
However, an increase in extracellular GABA level in the ipsilateral
SNr was detected and was even greater in hemiparkinsonian rats. A
recent in vivo electrophysiological study in intact rats also showed an
increase inGABAergic synaptic transmissionbyHFS-STN(Maurice
et al., 2003).This effectonGABAlevelwas abolishedbyGP lesioning
in intact and hemiparkinsonian rats. Thus, the stimulation of palli-
donigral neurons by HFS-STN is sufficient to account for the in-
crease in GABA release in the SNr, because GP neurons send axon
collaterals to the SNr (Kita and Kitai, 1987, 1994).
In deep brain stimulation, electrodes are placed in a complex
volume conductor in close proximity to somas, dendrites, and
presynaptic and postsynaptic axons. It is unclear which elements
are most susceptible to stimulation in our experiments (Ranck,
1975); however, in the cortex, axons have been reported to be
more sensitive than neuronal somas (Nowak and Bullier,
1998a,b) andmay be excited independently of soma depolarization
(Rattay, 1999). It has also been suggested that, during deep brain
stimulation, action potentials are initiated in the axons and may
propagate antidromically, invading the soma and dendrites (Grill
and McIntyre, 2001). GABAergic GP axons may be activated by
synaptic stimulation of GP neurons via the activation of sub-
thalamopallidal afferents or by direct stimulation ofGABAergic pal-
lidonigral fibers (Kita and Kitai, 1987, 1994). The former possibility
is unlikely becauseHFS-STNdidnot increaseGlu levels in theGP in
hemiparkinsonian rats. It therefore seemsmore probable that HFS-
STN activates GABAergic tracts passing close to the STN and that
such amechanism is responsible for theHFS-STN-induced increase
in GABA level in the SNr. The role of this process in the clinical
efficacy ofHFS-STN is unclear, but it could be partly responsible for
the inhibition of SNr neuron activity in vivo by HFS-STN in both
intact and 6-OHDA-treated rats (Tai et al., 2003).
In conclusion, this study indicates thatHFS-STN increases the
level of GABA in the SNr, probably by an activation of the palli-
donigral GABAergic pathway. The predominant effect of GABA
in the SNr that has been demonstrated recently (Windels and
Kiyatkin, 2004) supports the hypothesis that the increased GABA
level observedmay be actively involved in lessening the increased
excitatory influence of the Glu subthalamic pathway on the SNr
neurons in hemiparkinsonian rats. Through this action, HFS-
STNmay interfere with interactions involving direct and indirect
corticostriatal output circuits by inhibiting subthalamic circuits.
It will be of interest to determine to what extent this interference
is involved in counteracting neuronal abnormal activity within the
basal ganglia network caused by dopaminergic degeneration in PD
and therefore the exact role of this process in the clinical effects of
HFS-STN restoringmotor functions in parkinsonian patients.
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